Sign up
Pharma Capital

Athersys CEO highlights progress of lead therapy MultiStem to help stroke patients

Athersys Inc (NASDAQ: ATHX) CEO Dr. Gil Van Bokkelen together with patient and stroke victim Sharon Thomas joined Proactive Investors in New York to discuss how MultiStem, Athersys' lead therapy, is progressing through the drug-development cycle.

Thomas was treated with MultiStem when the drug was in Phase 2. It has since progressed to Phase 3 with FDA Fast Track designation. What's more, a separate clinical program evaluating MultiStem cell therapy for the treatment of Acute Respiratory Distress Syndrome has received Fast Track designation.

 

View full ATHX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.